Navigation Links
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7(R) in Turkey
Date:12/3/2008

SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced an exclusive, binding letter of intent with EIP Eczacibasi Ilac Pazarlama A.S. (EIP) for sales and marketing of the company's Allovectin-7(R) immunotherapeutic product candidate in Turkey and the Turkish Republic of Northern Cyprus. EIP has agreed to obtain the necessary regulatory approvals for the territory and to pay Vical upfront and milestone payments plus a specified transfer price in exchange for the rights to an exclusive license for the territory. EIP is a leading Turkish pharmaceutical company and has multiple licensing agreements with major biotech and pharmaceutical companies including Amgen, Pfizer, Procter & Gamble, and sanofi-aventis.

Vijay B. Samant, Vical's President and Chief Executive Officer, said, "As we advance toward completion of enrollment in our Phase 3 trial of Allovectin-7(R) in patients with advanced metastatic melanoma, we are also looking ahead to commercialization opportunities in key global markets. As an established pharmaceutical company in Turkey with a significant cancer franchise, EIP has the expertise to guide Allovectin-7(R) through the Turkish approval process and the strength to launch and sell Allovectin-7(R) successfully in the Turkish market. We continue to explore licensing and distribution agreements in additional international markets."

About Allovectin-7(R)

Allovectin-7(R) is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and beta-2 microglobulin, which together form a Class I Major Histocompatibility Complex, or MHC-I antigen. Injection of Allovectin-7(R) directly into tumors is designed to stimulate an immune response against both local and distant metastatic tumors. Vical conducted a large Phase 2 trial evaluating Allovectin-7(R) immunothera
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
3. U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vicals Vaxfectin(R) Adjuvant
4. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
5. First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease
6. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
7. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
8. Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
9. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
10. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)... , TURKU, Finland, July 3 B...ent company with its headquarters in Turku, Finlan...clinical trial of ProtoCure(TM),emulsion cream, t...his,double-blind, placebo-controlled study, condu...o moderate atopic dermatitis who applied the Proto...
(Date:7/1/2009)... , REYKJAVIK, Iceland, July 1 /PRNewswire-F... schizophrenia ever undertaken has revealed severa...ce of the human genome (SNPs) linked to,risk of t...um of scientists,led by a team from deCODE geneti... than 50,000 patients and control participants fro...
(Date:6/30/2009)... , SAN DIEGO, June 30 Accumetri... mark (1,600 patients) in the enrollment of its la...nsiveness with A V erifyNow(R) Assay I mpact on ...ically designed to demonstrate the value of provid...ients who are poor responders to clopidogrel (Plav...
(Date:6/29/2009)... , Prospective Study Seeks to Assess RSV Burden...Reinforcing Commitment to Pediatric Research , ...Immune continues to advance its commitment to pedi...rst observational prospective study designed to as...V) among preterm infants 32-to-35 weeks gestationa...
Breaking Medicine Technology:BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 2deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 3deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 4deCODE-led Megastudy Finds New Genetic Clues to Causes of Schizophrenia 5Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled 2MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 1Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 2Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 3Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 4Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 5Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 6Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 7Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 8Exjade 28R 29 Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs According to Landmark Trial 31624 9Align Technology Receives Expanded Regulatory Approval in Japan 9567 1Align Technology Receives Expanded Regulatory Approval in Japan 9567 2Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 1Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 2Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 3Quantros Acquires MEDMARX 28R 29 from United States Pharmacopeia 28USP 29 9565 4AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 1AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 2AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 3AstraZeneca and Targacept Announce Top Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia 3593 4
... - Neurologix, Inc.,(OTCBB:NRGX) today announced t... The Lancet of positive results from the first eve...he first report of,direct gene transfer into a pat...tive disease., The open label Phase 1 study, condu...ase demonstrated both a lack of adverse,events rel...
...- The,PromegaExpress(TM) on-site stocking program ...ne of on-site appliances. This,latest addition ser...ry requirements for smaller areas when space is at...ols is a necessity. The,mid-sized cabinet can also... freezer component., The entire line (see attached...
Other Medicine Technology:Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 2Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 3Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 4Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 5Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease 6
(Date:7/2/2009)...AAF Urge State Leaders to Support Principles to Go...lif., July 2 Nearly nin...rance companies have too much influence over how d...e (80%) voters support the concept of a "Health In... of guiding principles for health insurance compan...
(Date:7/2/2009)...SILVER, N.J., July 2 Dr Daniel Gol...rdinating a new study to measure the effectiveness...acute EKC -- a common, worldwide, highly contagiou... potential for long term visual impairment due to ...d the world are invited to register to participate...
(Date:7/2/2009)...res weight problems faced by youngsters with the d...ews) -- Children with type 1 diabetes are more lik...e, increasing their risk of serious health complic...a major study that explored the weight problems fa...s common form of the disease that usually shows up...
(Date:7/2/2009)...K, July 2 Tuesday night saw the la...cert in Barcelona where U2 kicked off their new to..., , (RED)ZONES are prime location areas directl...ughout the U2 tour. The tickets for the (RED)ZONE...rtion of the ticket sales going to the Global Fund...
Breaking Medicine News(10 mins):Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 2Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 3Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 4Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 5Health News:4 out of 5 CA Voters Demand Health Insurer "Code of Conduct" 6Health News:Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study 2Health News:Kids With Type 1 Diabetes Often Overweight 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 2Health News:(RED)ZONES Launch at First U2 360 Degrees Concert in Barcelona 3
...s children below the age of three are underweight ... bed hungry every day, says new data.// The Natio... Food Programme (WFP) say 45.9 percent of Indian c...erweight - they do not meet the standard weight in...
...r are quite frustrated by the large number of stra...cases// recorded by the main SMHS hospital here la...the last two months. 'The situation is alarming. W...y day. In some cases the victims are suspected to ...
...a pronounced risk of suffering weak bones due to t... Therefore, physicians need to be vigilant to spot...ording to the report the mix of sedentary behavior...allout of cancer, could result in suppression of b...
...CORT? for asthma provides a rapid and clinically s...t// in lung function within 15 minutes after admin...that in comparison to its monocomponents (budesoni...ORT and the other treatment groups containing form...
Other Medicine News:Health News:Bone Fragility, a Risk for Children With Cancer 2Health News:New Data Shows Significant Asthma Control With Symbicort 2
The CYPHER Sirolimus-eluting Coronary Stent consists of a proven antiproliferative drug, called "sirolimus", a controlled-release polymer, and a closed-cell stent delivery platform. Upon placement, s
The eNclose Anastomosis Assist Device was designed specifically to obviate the need for partial clamping of the aorta. The enclose device can provide the surgeon with a stable, bloodless field and im
15mm Open Blades, 30mm Maximum Blade Spread; in Titanium.
7mm Cross Hairs; Available in 4.5mm to 7.0mm in 0.5mm increments; Ring depth available from 2 to 4mm in 0.5mm increments.; in stainless steel.
Medicine Products: